The Resource Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos
Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos
Resource Information
The item Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in Sydney Jones Library, University of Liverpool.This item is available to borrow from 1 library branch.
Resource Information
The item Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in Sydney Jones Library, University of Liverpool.
This item is available to borrow from 1 library branch.
- Summary
- "Surgery in Systemic Autoimmune Disease, Volume 15, describes the state-of-the-art of the use of surgery in treating the most common systemic autoimmune diseases (SADS). The volume consists of an introductory chapter concerning the impact of surgery on SADs, follow by eight chapters describing the use of surgery in the treatment of specific diseases in various areas (cardiology, gastroenterology, orthopedics, neurology. etc.) and the possible difficulties and complications. The final five chapters deal with the possible complications arising during the course of biological and non-biological treatment, also providing recommendation concerning their management. International in scope, the list of more than 20 contributors from Europa and America reads like a who's who of clinical researchers in the field. Written by leading international clinical/surgical and scientific experts on surgical problems in SADsProvides a practical guide to the safer use of surgery in patients with autoimmune diseasesIncludes a number of problems and recommendations that cannot be found in other booksDesigned as a 'guide to clinical practice' for surgical interventions required by patients with SADsGives a comprehensive review of the available surgical options"--
- Language
- eng
- Extent
- 1 online resource.
- Contents
-
- Front Cover; Surgery in Rheumatic and Musculoskeletal Disease; Handbook of Systemic Autoimmune Diseases; Surgery in Rheumatic and Musculoskeletal Disease; Copyright; Dedication; Contents; List of Contributors; Preface; 1 -- The Spectrum of Rheumatic Diseases; 1. INTRODUCTION; 2. SYSTEMIC AUTOIMMUNE DISEASES; 2.1 Systemic Lupus Erythematosus; 2.2 Rheumatoid Arthritis; 2.3 Systemic Sclerosis; 2.4 Idiopathic Inflammatory Myopathies; 2.5 Antiphospholipid Syndrome; 3. AUTOINFLAMMATORY DISEASES; 4. METABOLIC DISEASES; 4.1 Osteoporosis; 4.2 Crystal Deposition Disease
- 4.2.1 Calcium Pyrophosphate Disease (CPPD)4.3 Gout; 5. DEGENERATIVE DISEASES; 5.1 Osteoarthritis; 6. CONCLUSIONS; KEYPOINTS; REFERENCES; 2 -- Comorbidities in Patients With Rheumatic Disease; 1. INTRODUCTION; 1.1 The Concepts of Comorbidity and Multimorbidity; 1.2 Prevalence of Multimorbidity in Rheumatic Conditions; 2. ASSESSMENT OF COMORBID CONDITIONS; 3. IMPACT OF COMORBIDITIES ON IMPORTANT OUTCOMES; 3.1 Mortality; 3.2 Health Economic Implications; 3.3 Disease-Related Outcomes; 3.4 Outcomes Related to Surgery; 4. DISTINCT COMORBID CONDITIONS; 4.1 Cardiovascular Disease
- 4.2 Pulmonary Disease4.3 Malignancies; 4.4 Gastrointestinal Disease; 4.5 Infections; 4.6 Osteoporosis; 4.7 Depression; 5. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; REFERENCES; 3 -- Drugs Used in Rheumatic Disease; 1. INTRODUCTION; 2. NONSTEROIDAL ANTIINFLAMMATORY DRUGS; 3. GLUCOCORTICOIDS; 4. IMMUNOSUPPRESSANTS/IMMUNOMODULATORS AND DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 4.1 Nonbiological Agents; 4.1.1 Methotrexate; 4.1.2 Leflunomide; 4.1.3 Sulfasalazine; 4.1.4 Antimalarials; 4.1.5 Cyclophosphamide; 4.1.6 Azatihioprine; 4.1.7 Mycophenolate Mofetil
- 4.1.8 Cyclosporine and Tacrolimus4.1.9 Apremilast; 4.1.10 Tofacitinib; 4.2 Biologicals; 4.2.1 Tumor Necrosis Factor-Alpha Inhibitors; 4.2.2 Tocilizumab; 4.2.3 Anakinra, Canakinumab, and Rilonacept; 4.2.4 Rituximab; 4.2.5 Abatacept; 4.2.6 Secukinumab; 4.2.7 Ustekinumab; 4.2.8 Belimumab; 5. COLCHICINE; 6. URATE-LOWERING AGENTS; 7. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; DEDICATION; REFERENCES; 4 -- Essential and Optional Drugs for Rheumatic Diseases; 1. RHEUMATOID ARTHRITIS AND SPONDYLARTHRITIDES; 2. GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA; 3. VASCULITIDES
- 4. CONNECTIVE TISSUE DISEASES5. BASIC LABORATORY ASSESSMENT; 6. GLUCOCORTICOIDS; 7. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; 8. DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 9. ANTIMALARIALS; 10. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 10.1 Methotrexate; 10.2 Sulfasalazine; 10.3 Leflunomide; 11. BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 11.1 Tumor Necrosis Factor Blockers (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab); 11.2 Interleukin-1 (Receptor) Blockade (Anakinra, Canakinumab); 11.3 Interleukin-6 (Receptor) Blockade (Sarilumab, Tocilizumab)
- Isbn
- 9780444638885
- Label
- Surgery in rheumatic and musculoskeletal disease
- Title
- Surgery in rheumatic and musculoskeletal disease
- Statement of responsibility
- editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos
- Language
- eng
- Summary
- "Surgery in Systemic Autoimmune Disease, Volume 15, describes the state-of-the-art of the use of surgery in treating the most common systemic autoimmune diseases (SADS). The volume consists of an introductory chapter concerning the impact of surgery on SADs, follow by eight chapters describing the use of surgery in the treatment of specific diseases in various areas (cardiology, gastroenterology, orthopedics, neurology. etc.) and the possible difficulties and complications. The final five chapters deal with the possible complications arising during the course of biological and non-biological treatment, also providing recommendation concerning their management. International in scope, the list of more than 20 contributors from Europa and America reads like a who's who of clinical researchers in the field. Written by leading international clinical/surgical and scientific experts on surgical problems in SADsProvides a practical guide to the safer use of surgery in patients with autoimmune diseasesIncludes a number of problems and recommendations that cannot be found in other booksDesigned as a 'guide to clinical practice' for surgical interventions required by patients with SADsGives a comprehensive review of the available surgical options"--
- Assigning source
- Provided by publisher
- Cataloging source
- N$T
- Dewey number
- 617.4
- Index
- index present
- LC call number
- RD605.2
- Literary form
- non fiction
- Nature of contents
-
- dictionaries
- bibliography
- http://library.link/vocab/relatedWorkOrContributorName
-
- Atzeni, Fabiola
- Masala, Ignazio Francesco
- Aletaha, Daniel
- Series statement
- Handbook of systemic autoimmune diseases
- Series volume
- 15
- http://library.link/vocab/subjectName
-
- Autoimmune diseases
- Rheumatism
- Musculoskeletal system
- Label
- Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos
- Antecedent source
- unknown
- Bibliography note
- Includes bibliographical references and index
- Carrier category
- online resource
- Carrier category code
-
- cr
- Carrier MARC source
- rdacarrier
- Color
- multicolored
- Content category
- text
- Content type code
-
- txt
- Content type MARC source
- rdacontent
- Contents
-
- Front Cover; Surgery in Rheumatic and Musculoskeletal Disease; Handbook of Systemic Autoimmune Diseases; Surgery in Rheumatic and Musculoskeletal Disease; Copyright; Dedication; Contents; List of Contributors; Preface; 1 -- The Spectrum of Rheumatic Diseases; 1. INTRODUCTION; 2. SYSTEMIC AUTOIMMUNE DISEASES; 2.1 Systemic Lupus Erythematosus; 2.2 Rheumatoid Arthritis; 2.3 Systemic Sclerosis; 2.4 Idiopathic Inflammatory Myopathies; 2.5 Antiphospholipid Syndrome; 3. AUTOINFLAMMATORY DISEASES; 4. METABOLIC DISEASES; 4.1 Osteoporosis; 4.2 Crystal Deposition Disease
- 4.2.1 Calcium Pyrophosphate Disease (CPPD)4.3 Gout; 5. DEGENERATIVE DISEASES; 5.1 Osteoarthritis; 6. CONCLUSIONS; KEYPOINTS; REFERENCES; 2 -- Comorbidities in Patients With Rheumatic Disease; 1. INTRODUCTION; 1.1 The Concepts of Comorbidity and Multimorbidity; 1.2 Prevalence of Multimorbidity in Rheumatic Conditions; 2. ASSESSMENT OF COMORBID CONDITIONS; 3. IMPACT OF COMORBIDITIES ON IMPORTANT OUTCOMES; 3.1 Mortality; 3.2 Health Economic Implications; 3.3 Disease-Related Outcomes; 3.4 Outcomes Related to Surgery; 4. DISTINCT COMORBID CONDITIONS; 4.1 Cardiovascular Disease
- 4.2 Pulmonary Disease4.3 Malignancies; 4.4 Gastrointestinal Disease; 4.5 Infections; 4.6 Osteoporosis; 4.7 Depression; 5. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; REFERENCES; 3 -- Drugs Used in Rheumatic Disease; 1. INTRODUCTION; 2. NONSTEROIDAL ANTIINFLAMMATORY DRUGS; 3. GLUCOCORTICOIDS; 4. IMMUNOSUPPRESSANTS/IMMUNOMODULATORS AND DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 4.1 Nonbiological Agents; 4.1.1 Methotrexate; 4.1.2 Leflunomide; 4.1.3 Sulfasalazine; 4.1.4 Antimalarials; 4.1.5 Cyclophosphamide; 4.1.6 Azatihioprine; 4.1.7 Mycophenolate Mofetil
- 4.1.8 Cyclosporine and Tacrolimus4.1.9 Apremilast; 4.1.10 Tofacitinib; 4.2 Biologicals; 4.2.1 Tumor Necrosis Factor-Alpha Inhibitors; 4.2.2 Tocilizumab; 4.2.3 Anakinra, Canakinumab, and Rilonacept; 4.2.4 Rituximab; 4.2.5 Abatacept; 4.2.6 Secukinumab; 4.2.7 Ustekinumab; 4.2.8 Belimumab; 5. COLCHICINE; 6. URATE-LOWERING AGENTS; 7. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; DEDICATION; REFERENCES; 4 -- Essential and Optional Drugs for Rheumatic Diseases; 1. RHEUMATOID ARTHRITIS AND SPONDYLARTHRITIDES; 2. GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA; 3. VASCULITIDES
- 4. CONNECTIVE TISSUE DISEASES5. BASIC LABORATORY ASSESSMENT; 6. GLUCOCORTICOIDS; 7. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; 8. DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 9. ANTIMALARIALS; 10. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 10.1 Methotrexate; 10.2 Sulfasalazine; 10.3 Leflunomide; 11. BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 11.1 Tumor Necrosis Factor Blockers (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab); 11.2 Interleukin-1 (Receptor) Blockade (Anakinra, Canakinumab); 11.3 Interleukin-6 (Receptor) Blockade (Sarilumab, Tocilizumab)
- Control code
- SCIDI1029872305
- Dimensions
- unknown
- Extent
- 1 online resource.
- File format
- unknown
- Form of item
- online
- Isbn
- 9780444638885
- Level of compression
- unknown
- Media category
- computer
- Media MARC source
- rdamedia
- Media type code
-
- c
- Note
- Online access with subscription: Elsevier (Sciencedirect Freedom Collection)
- Quality assurance targets
- not applicable
- Reformatting quality
- unknown
- Sound
- unknown sound
- Specific material designation
- remote
- System control number
-
- on1029872305
- (OCoLC)1029872305
- Label
- Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos
- Antecedent source
- unknown
- Bibliography note
- Includes bibliographical references and index
- Carrier category
- online resource
- Carrier category code
-
- cr
- Carrier MARC source
- rdacarrier
- Color
- multicolored
- Content category
- text
- Content type code
-
- txt
- Content type MARC source
- rdacontent
- Contents
-
- Front Cover; Surgery in Rheumatic and Musculoskeletal Disease; Handbook of Systemic Autoimmune Diseases; Surgery in Rheumatic and Musculoskeletal Disease; Copyright; Dedication; Contents; List of Contributors; Preface; 1 -- The Spectrum of Rheumatic Diseases; 1. INTRODUCTION; 2. SYSTEMIC AUTOIMMUNE DISEASES; 2.1 Systemic Lupus Erythematosus; 2.2 Rheumatoid Arthritis; 2.3 Systemic Sclerosis; 2.4 Idiopathic Inflammatory Myopathies; 2.5 Antiphospholipid Syndrome; 3. AUTOINFLAMMATORY DISEASES; 4. METABOLIC DISEASES; 4.1 Osteoporosis; 4.2 Crystal Deposition Disease
- 4.2.1 Calcium Pyrophosphate Disease (CPPD)4.3 Gout; 5. DEGENERATIVE DISEASES; 5.1 Osteoarthritis; 6. CONCLUSIONS; KEYPOINTS; REFERENCES; 2 -- Comorbidities in Patients With Rheumatic Disease; 1. INTRODUCTION; 1.1 The Concepts of Comorbidity and Multimorbidity; 1.2 Prevalence of Multimorbidity in Rheumatic Conditions; 2. ASSESSMENT OF COMORBID CONDITIONS; 3. IMPACT OF COMORBIDITIES ON IMPORTANT OUTCOMES; 3.1 Mortality; 3.2 Health Economic Implications; 3.3 Disease-Related Outcomes; 3.4 Outcomes Related to Surgery; 4. DISTINCT COMORBID CONDITIONS; 4.1 Cardiovascular Disease
- 4.2 Pulmonary Disease4.3 Malignancies; 4.4 Gastrointestinal Disease; 4.5 Infections; 4.6 Osteoporosis; 4.7 Depression; 5. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; REFERENCES; 3 -- Drugs Used in Rheumatic Disease; 1. INTRODUCTION; 2. NONSTEROIDAL ANTIINFLAMMATORY DRUGS; 3. GLUCOCORTICOIDS; 4. IMMUNOSUPPRESSANTS/IMMUNOMODULATORS AND DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 4.1 Nonbiological Agents; 4.1.1 Methotrexate; 4.1.2 Leflunomide; 4.1.3 Sulfasalazine; 4.1.4 Antimalarials; 4.1.5 Cyclophosphamide; 4.1.6 Azatihioprine; 4.1.7 Mycophenolate Mofetil
- 4.1.8 Cyclosporine and Tacrolimus4.1.9 Apremilast; 4.1.10 Tofacitinib; 4.2 Biologicals; 4.2.1 Tumor Necrosis Factor-Alpha Inhibitors; 4.2.2 Tocilizumab; 4.2.3 Anakinra, Canakinumab, and Rilonacept; 4.2.4 Rituximab; 4.2.5 Abatacept; 4.2.6 Secukinumab; 4.2.7 Ustekinumab; 4.2.8 Belimumab; 5. COLCHICINE; 6. URATE-LOWERING AGENTS; 7. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; DEDICATION; REFERENCES; 4 -- Essential and Optional Drugs for Rheumatic Diseases; 1. RHEUMATOID ARTHRITIS AND SPONDYLARTHRITIDES; 2. GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA; 3. VASCULITIDES
- 4. CONNECTIVE TISSUE DISEASES5. BASIC LABORATORY ASSESSMENT; 6. GLUCOCORTICOIDS; 7. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; 8. DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 9. ANTIMALARIALS; 10. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 10.1 Methotrexate; 10.2 Sulfasalazine; 10.3 Leflunomide; 11. BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 11.1 Tumor Necrosis Factor Blockers (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab); 11.2 Interleukin-1 (Receptor) Blockade (Anakinra, Canakinumab); 11.3 Interleukin-6 (Receptor) Blockade (Sarilumab, Tocilizumab)
- Control code
- SCIDI1029872305
- Dimensions
- unknown
- Extent
- 1 online resource.
- File format
- unknown
- Form of item
- online
- Isbn
- 9780444638885
- Level of compression
- unknown
- Media category
- computer
- Media MARC source
- rdamedia
- Media type code
-
- c
- Note
- Online access with subscription: Elsevier (Sciencedirect Freedom Collection)
- Quality assurance targets
- not applicable
- Reformatting quality
- unknown
- Sound
- unknown sound
- Specific material designation
- remote
- System control number
-
- on1029872305
- (OCoLC)1029872305
Library Links
Embed
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.liverpool.ac.uk/portal/Surgery-in-rheumatic-and-musculoskeletal-disease/rTPsERIC6WU/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.liverpool.ac.uk/portal/Surgery-in-rheumatic-and-musculoskeletal-disease/rTPsERIC6WU/">Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.liverpool.ac.uk/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.liverpool.ac.uk/">Sydney Jones Library, University of Liverpool</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Item Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.liverpool.ac.uk/portal/Surgery-in-rheumatic-and-musculoskeletal-disease/rTPsERIC6WU/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.liverpool.ac.uk/portal/Surgery-in-rheumatic-and-musculoskeletal-disease/rTPsERIC6WU/">Surgery in rheumatic and musculoskeletal disease, editors, Fabiola Atzeni, Ignazio Francesco Masala, Daniel Aletaha, Marcus Lee, Xenofon Baraliakos</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.liverpool.ac.uk/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.liverpool.ac.uk/">Sydney Jones Library, University of Liverpool</a></span></span></span></span></div>
